A Phase 4 interventional study of Brentuximab vedotin in T-Cell Lymphoma, sponsored by Takeda. Completed at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by Takeda · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Brentuximab Vedotin in Lymphoma, T-Cell — 1 open to participants now, 2 under way, none of them phase 3. Brentuximab Vedotin · Lymphoma, T-Cell.
Among the 12 studies testing Brentuximab Vedotin in Lymphoma, T-Cell, this one is the 10th largest by enrollment, is the only one that started in 2022, is one of 2 in phase 4, and was the 12th registered.
310 studies on the registry are indexed under Lymphoma, T-Cell; 77 are open to participants now.
Browse Lymphoma, T-Cell studies →1 of the 12 studies testing Brentuximab Vedotin in Lymphoma, T-Cell is open now, in 1 country. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 18+
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 67 Lymphoma, T-Cell studies recruiting now, 41 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 37 across 270 interventional studies indexed under Lymphoma, T-Cell.
Median enrollment 36 across the 12 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 12 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 4 studies filed under Lymphoma, T-Cell — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing Brentuximab Vedotin in Lymphoma, T-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main aim is to check the long-term side effects of treatment with Brentuximab Vedotin and to see if that treatment improves symptoms of cluster of differentiation antigen 30 (CD30-Positive) Cutaneous T-Cell Lymphoma in Chinese adults.
Participants will receive brentuximab vedotin through the vein on day 1 of each 21 day cycle up to maximum 16 cycles.
The drug being tested in this study is called brentuximab vedotin (SGN-35). Brentuximab vedotin is being tested to treat people who have CD30-positive cutaneous T-Cell lymphoma.
The study will enroll approximately 10 patients. Participants will receive a single treatment i.e., brentuximab vedotin monotherapy:
Participants will be administered with brentuximab vedotin by intravenous (IV) infusion given for approximately 30 minutes on Day 1 of each 21-day cycle up to 16 cycles followed by the end of treatment (EOT) visit 30 days after receiving the final dose of study drug. Participants with progressive disease (PD) at any time during the study will be discontinued from study drug.
This multi-center trial will be conducted in China. Participants will remain in this study for approximately 56 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. - confirmed cluster of differentiation antigen 30 positive (CD30+) disease by local laboratory assessment and pathology review.
2. Participants with primary cutaneous anaplastic large cell lymphoma (pcALCL) who have received prior radiation therapy or at least 1 prior systemic therapy, or participants with mycosis fungoides (MF) who have received at least 1 prior systemic therapy for their disease. 3. (ECOG) performance status of ≤2. 4. Suitable venous access for the study-required blood sampling. 5. Participants must have radiographically or clinically measurable or evaluable disease.
6. Recovered (i.e., Grade 1 toxicity) from the reversible effects of prior antineoplastic therapy.
-Exclusion Criteria:
Any of the following cardiovascular conditions or values within 6 months before the first dose of study drug:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received brentuximab vedotin 1.8 milligrams per kilogram (mg/kg), IV on Day 1 of each 21-day cycle for up to a total of 16 cycles.
Drug: Brentuximab vedotin
Brentuximab vedotin IV infusion.
Also known as: SGN-35
Overall Response Rate (ORR) Lasting at Least 4 Months in Participants With CD30+ MF or pcALCL
ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) that lasts at least 4 months. CR is defined as complete disappearance of all clinical evidence of disease and PR is defined as regression of measurable disease. ORR was determined based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral involvement using computed tomography (CT) scan, and for the participants with mycosis fungoides (MF) only, detection of circulating Sezary cells. Response Criteria were based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines.
Time frame: Up to 58 weeks
Complete Response (CR) Rate
CR rate is defined as the percentage of participants with CR. CR is defined as complete disappearance of all clinical evidence of disease. CR was determined based on GRS which consisted of a skin assessment by the investigator using the mSWAT, nodal and visceral involvement using computed tomography (CT) scan, and for the participants with MF only, detection of circulating Sezary cells. Response Criteria were based on ISCL, USCLC and EORTC Consensus guidelines.
Time frame: Up to 58 weeks
Overall Response Rate (ORR)
ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR). CR is defined as complete disappearance of all clinical evidence of disease and PR is defined as regression of measurable disease. ORR was determined based on GRS which consisted of a skin assessment by the investigator using the mSWAT, nodal and visceral involvement using CT scan, and for the participants with MF only, detection of circulating Sezary cells. Response Criteria were based on ISCL, USCLC and EORTC Consensus guidelines.
Time frame: Up to 58 weeks
Duration of Response (DOR)
Duration of response was assessed in participants with CR or PR and is defined as the time between first documentation of response and progressive disease (PD). Response criteria were based on ISCL, USCLC and EORTC Consensus guidelines. Participants who were lost to follow-up, withdrew consent, or discontinued treatment due to undocumented PD after the last adequate disease assessment were censored at the last disease assessment.
Time frame: Up to 58 weeks
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g. a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAE is defined as an adverse event with an onset that occurs after receiving study drug. SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. TEAE and SAE were determined as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.
Time frame: From first dose of study drug through 30 days after the last dose of study drug (up to approximately 58 weeks)
Changes From Baseline in Participant's Vital Sign: Systolic and Diastolic Blood Pressure
Vital signs included seated blood pressure (systolic and diastolic) measurements.
Time frame: Baseline, at end of treatment (approximately Week 54)
Changes From Baseline in Participant's Vital Sign: Heart Rate
Vital signs included heart rate (beats per minute) measurements.
Time frame: Baseline, at end of treatment (approximately Week 54)
Changes From Baseline in Participant's Vital Sign: Body Temperature
Vital signs included body temperature (degree Celsius) measurements.
Time frame: Baseline, at end of treatment (approximately Week 54)
Number of Participants From Baseline to Worst Post-Baseline Assessment Categories Based on Eastern Cooperative Oncology Group (ECOG) Performance Status Scale
ECOG scale was used to assess performance status of participants. Grades range from 0 (fully active) to 5 (dead) where Grade 0: Normal activity. Grade 1: Symptoms but ambulatory. Grade 2: In bed \<50% of the time. Grade 3: In bed \>50% of the time. Grade 4: 100% bedridden. Grade 5: Dead. Lower grades indicate improvement. Reported here is the number of participants in each reported baseline grade to their worst post-baseline grade assessment on the ECOG scale.
Time frame: Baseline up to 30 days after the last dose of study drug (up to approximately 58 weeks)
Change From Baseline in Hematology Parameter: Hemoglobin
Time frame: Baseline, at end of treatment (approximately Week 54)
Change From Baseline in Hematology Parameter: Neutrophil Count
Time frame: Baseline, at end of treatment (approximately Week 54)
Change From Baseline in Hematology Parameter: Platelet Count
Time frame: Baseline, at end of treatment (approximately Week 54)
Change From Baseline in Hematology Parameter: Lymphocyte Count
Time frame: Baseline, at end of treatment (approximately Week 54)
Change From Baseline in Hematology Parameter: Leukocyte Count
Time frame: Baseline, at end of treatment (approximately Week 54)
Change From Baseline in Serum Chemistry Parameter: Alkaline Phosphatase (ALP)
Time frame: Baseline, at end of treatment (approximately Week 54)
Change From Baseline in Serum Chemistry Parameter: Alanine Aminotransferase (ALT)
Time frame: Baseline, at end of treatment (approximately Week 54)
Change From Baseline in Serum Chemistry Parameter: Aspartate Aminotransferase (AST)
Time frame: Baseline, at end of treatment (approximately Week 54)
Change From Baseline in Serum Chemistry Parameter: Total Bilirubin
Time frame: Baseline, at end of treatment (approximately Week 54)
Change From Baseline in Serum Chemistry Parameter: Lipase
Time frame: Baseline, at end of treatment (approximately Week 54)
Change From Baseline in Serum Chemistry Parameter: Amylase
Time frame: Baseline, at end of treatment (approximately Week 54)
Participants took part in the study at 3 investigative sites in China from 28 November 2022 to 09 August 2024.
| Milestone | Brentuximab Vedotin |
|---|---|
| Started | 10 |
| Completed | 9 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) that lasts at least 4 months. CR is defined as complete disappearance of all clinical evidence of disease and PR is defined as regression of measurable disease. ORR was determined based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral involvement using computed tomography (CT) scan, and for the participants with mycosis fungoides (MF) only, detection of circulating Sezary cells. Response Criteria were based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines.
| percentage of participants | Brentuximab Vedotin |
|---|---|
| Overall Response Rate (ORR) Lasting at Least 4 Months in Participants With CD30+ MF or pcALCL | 60.0 (26.2 to 87.8) |
CR rate is defined as the percentage of participants with CR. CR is defined as complete disappearance of all clinical evidence of disease. CR was determined based on GRS which consisted of a skin assessment by the investigator using the mSWAT, nodal and visceral involvement using computed tomography (CT) scan, and for the participants with MF only, detection of circulating Sezary cells. Response Criteria were based on ISCL, USCLC and EORTC Consensus guidelines.
| percentage of participants | Brentuximab Vedotin |
|---|---|
| Complete Response (CR) Rate | 0 (0 to 30.8) |
ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR). CR is defined as complete disappearance of all clinical evidence of disease and PR is defined as regression of measurable disease. ORR was determined based on GRS which consisted of a skin assessment by the investigator using the mSWAT, nodal and visceral involvement using CT scan, and for the participants with MF only, detection of circulating Sezary cells. Response Criteria were based on ISCL, USCLC and EORTC Consensus guidelines.
| percentage of participants | Brentuximab Vedotin |
|---|---|
| Overall Response Rate (ORR) | 70.0 (34.8 to 93.3) |
Duration of response was assessed in participants with CR or PR and is defined as the time between first documentation of response and progressive disease (PD). Response criteria were based on ISCL, USCLC and EORTC Consensus guidelines. Participants who were lost to follow-up, withdrew consent, or discontinued treatment due to undocumented PD after the last adequate disease assessment were censored at the last disease assessment.
| months | Brentuximab Vedotin |
|---|---|
| Duration of Response (DOR) | NA (NA to NA) |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g. a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. TEAE is defined as an adverse event with an onset that occurs after receiving study drug. SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. TEAE and SAE were determined as per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.
| Participants | Brentuximab Vedotin |
|---|---|
| TEAEs | 10 |
| SAEs | 4 |
Vital signs included seated blood pressure (systolic and diastolic) measurements.
| millimeters of mercury (mmHg) | Brentuximab Vedotin |
|---|---|
| Systolic Blood Pressure: Baseline | 125.6 ± 11.04 |
| Systolic Blood Pressure: Change from Baseline at the End of Treatment | -2.9 ± 8.81 |
| Diastolic Blood Pressure: Baseline | 76.5 ± 6.36 |
| Diastolic Blood Pressure: Change from Baseline at the End of Treatment | -4.4 ± 4.61 |
Vital signs included heart rate (beats per minute) measurements.
| beats per minute | Brentuximab Vedotin |
|---|---|
| Baseline | 87.4 ± 10.11 |
| Change from Baseline at the End of Treatment | -10.3 ± 14.34 |
Vital signs included body temperature (degree Celsius) measurements.
| degree Celsius (°C) | Brentuximab Vedotin |
|---|---|
| Baseline | 36.62 ± 0.368 |
| Change from Baseline at the End of Treatment | 0.00 ± 0.361 |
ECOG scale was used to assess performance status of participants. Grades range from 0 (fully active) to 5 (dead) where Grade 0: Normal activity. Grade 1: Symptoms but ambulatory. Grade 2: In bed \<50% of the time. Grade 3: In bed \>50% of the time. Grade 4: 100% bedridden. Grade 5: Dead. Lower grades indicate improvement. Reported here is the number of participants in each reported baseline grade to their worst post-baseline grade assessment on the ECOG scale.
| Participants | Brentuximab Vedotin |
|---|---|
| Participants with Baseline Grade: 0 to Worst Post-Baseline Grade: 0 | 2 |
| Participants with Baseline Grade: 1 to Worst Post-Baseline Grade: 1 | 7 |
| Participants with Baseline Grade: 1 to Worst Post-Baseline Grade: 3 | 1 |
| grams per liter (g/L) | Brentuximab Vedotin |
|---|---|
| Baseline | 126.3 ± 23.00 |
| Change from baseline at the End of Treatment | -5.4 ± 16.46 |
| 10^9 cells/liter (L) | Brentuximab Vedotin |
|---|---|
| Baseline | 3.949 ± 2.2230 |
| Change from Baseline at the End of Treatment | 0.189 ± 4.4084 |
| 10^9 cells/L | Brentuximab Vedotin |
|---|---|
| Baseline | 279.2 ± 78.24 |
| Change from Baseline at the End of Treatment | -97.0 ± 86.87 |
| 10^9 cells/L | Brentuximab Vedotin |
|---|---|
| Baseline | 1.530 ± 0.7367 |
| Change from Baseline at the End of Treatment | -0.101 ± 0.3355 |
| 10^9 cells/L | Brentuximab Vedotin |
|---|---|
| Baseline | 7.082 ± 3.1018 |
| Change from Baseline at the End of Treatment | -0.862 ± 3.5380 |
| Units per liter (U/L) | Brentuximab Vedotin |
|---|---|
| Baseline | 89.0 ± 29.66 |
| Change from Baseline at the End of Treatment | 26.3 ± 36.10 |
| U/L | Brentuximab Vedotin |
|---|---|
| Baseline | 18.9 ± 10.45 |
| Change from Baseline at the End of Treatment | 8.2 ± 15.52 |
| U/L | Brentuximab Vedotin |
|---|---|
| Baseline | 19.0 ± 5.85 |
| Change from Baseline at the End of Treatment | 10.7 ± 10.40 |
| micromoles per liter (µmol/L) | Brentuximab Vedotin |
|---|---|
| Baseline | 8.82 ± 3.879 |
| Change from Baseline at the End of Treatment | 1.93 ± 3.947 |
| U/L | Brentuximab Vedotin |
|---|---|
| Baseline | 35.96 ± 10.726 |
| Change from Baseline at the End of Treatment | 4.90 ± 11.837 |
| U/L | Brentuximab Vedotin |
|---|---|
| Baseline | 64.0 ± 24.55 |
| Change from Baseline at the End of Treatment | 10.9 ± 25.80 |
Collected over Up to 58 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brentuximab Vedotin | 0/10 (0%) | 4/10 (40%) | 10/10 (100%) |
| Event | Brentuximab Vedotin |
|---|---|
| DysuriaRenal and urinary disorders | 1/10 |
| Neuropathy peripheralNervous system disorders | 1/10 |
| Oedema peripheralGeneral disorders | 1/10 |
| Renal tubular necrosisRenal and urinary disorders | 1/10 |
| White blood cell count decreasedInvestigations | 1/10 |
| Event | Brentuximab Vedotin |
|---|---|
| PyrexiaGeneral disorders | 4/10 |
| AnaemiaBlood and lymphatic system disorders | 3/10 |
| FatigueGeneral disorders | 3/10 |
| Gamma-glutamyltransferase increasedInvestigations | 3/10 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 3/10 |
| Alanine aminotransferase increasedInvestigations | 2/10 |
| AlopeciaSkin and subcutaneous tissue disorders | 2/10 |
| Aspartate aminotransferase increasedInvestigations | 2/10 |
| Blood alkaline phosphatase increasedInvestigations | 2/10 |
| Blood creatine phosphokinase increasedInvestigations | 2/10 |
The safety analysis set consisted of all enrolled participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Brentuximab Vedotin |
|---|---|
| Mean | 57.1 ± 13.26 |
| Sex: Female, Male(Participants) | Brentuximab Vedotin |
|---|---|
| Female | 5 |
| Male | 5 |
| Ethnicity (NIH/OMB)(Participants) | Brentuximab Vedotin |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 10 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Brentuximab Vedotin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 10 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Takeda does not provide access to Individual Participant Data when a study is in a very limited (small) study population due to participant privacy concerns such as potential reidentification of study participants.
Ran from Nov 2022 to primary completion in Aug 2024, 20 months.
Results were first posted in Aug 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin